Get the Stockscreener App
0.7399
1.08%
-0.0081
After Hours:
.75
0.0101
+1.37%
Beyond Air Inc stock is traded at $0.7399, with a volume of 96,731.
It is down -1.08% in the last 24 hours and down -20.15% over the past month.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
See More
Previous Close:
$0.748
Open:
$0.7498
24h Volume:
96,731
Relative Volume:
0.01
Market Cap:
$7.79M
Revenue:
$6.92M
Net Income/Loss:
$-32.03M
P/E Ratio:
-0.1365
EPS:
-5.4201
Net Cash Flow:
$-22.13M
1W Performance:
-8.31%
1M Performance:
-20.15%
6M Performance:
-68.24%
1Y Performance:
+152.78%
1-Day Range:
$0.7303
$0.7749
1-Week Range:
$0.7303
$0.81
52-Week Range:
$0.1521
$4.78
Beyond Air Inc Stock (XAIR) Company Profile
Name
Beyond Air Inc
Sector
Industry
Phone
516-665-8200
Address
900 STEWART AVENUE, GARDEN CITY, NY
Compare XAIR vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XAIR
Beyond Air Inc
|
0.7399 | 7.88M | 6.92M | -32.03M | -22.13M | -5.4201 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Beyond Air Inc Stock (XAIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-25 | Initiated | D. Boral Capital | Buy |
| Jun-25-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-28-23 | Initiated | Piper Sandler | Overweight |
| Jun-15-23 | Initiated | BTIG Research | Buy |
| Apr-28-21 | Initiated | Truist | Buy |
| Oct-22-19 | Initiated | Oppenheimer | Outperform |
View All
Beyond Air Inc Stock (XAIR) Latest News
Signal Recap: Is Beyond Air Inc showing insider buyingMarket Risk Report & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Earnings Risk: Will Beyond Air Inc stock benefit from M AWeekly Trade Recap & Low Risk Entry Point Guides - baoquankhu1.vn
Beyond Air appoints Duke Drewell as interim CFO - MSN
Form 8K Beyond Air Inc For: 15 January - Investing.com
Beyond Air, Inc. Trade Ideas — GETTEX:48L0 - TradingView
Beyond Air (XAIR) Retains 'Buy' Rating with $10 PT by D. Boral C - GuruFocus
Beyond Air (XAIR) Sees Promising Phase 1 Trial Results for Cance - GuruFocus
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial - The Manila Times
High-dose nitric oxide shot shows early activity in small cancer trial - Stock Titan
Beyond Air at Life Sciences Forum: Strategic Innovations in Medical Devices - Investing.com Canada
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR) - The Globe and Mail
XAIR: Second-generation nitric oxide system targets global growth and improved hospital adoption - TradingView
Beyond Air to Participate in the 38th Annual Roth Conference in March - The Manila Times
Beyond Air terminates NeuroNOS sale talks with XTL Biopharmaceuticals By Investing.com - Investing.com Canada
Beyond Air terminates NeuroNOS sale talks with XTL Biopharmaceuticals - Investing.com South Africa
XTL Biopharmaceuticals (NASDAQ: XTLB) NeuroNOS deal LOI expires with Beyond Air - Stock Titan
Beyond Air (XAIR) Buy Rating Reaffirmed by D. Boral Capital | XA - GuruFocus
Beyond Air Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. - Bitget
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd. - The Manila Times
Beyond Air drops NeuroNOS sale, rethinks neurological and cancer plans - Stock Titan
XTL Biopharmaceuticals Ltd. cancelled the acquisition of 85% stake in NeuroNos Limited from Beyond Air, Inc.. - marketscreener.com
New Highs: Is Beyond Air Inc stock a falling knife or bargain buy2025 Biggest Moves & Verified Momentum Stock Watchlist - baoquankhu1.vn
Technical Analysis: Can Beyond Air Inc continue delivering strong returns2025 Risk Factors & Verified Short-Term Trading Plans - baoquankhu1.vn
Insider Sell: Will Beyond Air Inc benefit from geopolitical trends2025 Short Interest & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Swing Trade: Is Beyond Air Inc stock a buy or sellWeekly Trading Summary & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies - Finviz
12 Best NASDAQ Penny Stocks to Buy According to Analysts - Insider Monkey
Published on: 2026-03-02 20:03:07 - baoquankhu1.vn
Bull Bear: Can Beyond Air Inc deliver consistent EPS growthJuly 2025 Setups & Stock Portfolio Risk Management - baoquankhu1.vn
XAIR Should I Buy - Intellectia AI
XAIR PE Ratio & Valuation, Is XAIR Overvalued - Intellectia AI
How The Narrative On Beyond Air (XAIR) Is Resetting Around LungFit PH And Delayed Approval - Yahoo Finance
Earnings Beat: What is the PEG ratio of Beyond Air IncJuly 2025 Final Week & Real-Time Chart Pattern Alerts - baoquankhu1.vn
XAIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Beyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressive Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Beyond Air Inc (XAIR) Q3 2026 Earnings Call Highlights: Impressi - GuruFocus
Balyasny Asset Management L.P. Increases Stake in Beyond Air Inc - GuruFocus
Beyond Air comments on review of high-dose nitric oxide therapy - Investing.com Nigeria
Beyond Air (XAIR) Highlights Potential of High-Dose Inhaled Nitr - GuruFocus
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections - The Manila Times
Beyond Air, Inc. Highlights Comprehensive Review on High-Dose Inhaled Nitric Oxide as Potential Antimicrobial Therapy for Respiratory Infections - Quiver Quantitative
Beyond Air Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections - Bitget
High-dose inhaled gas shows promise against tough lung infections - Stock Titan
Published on: 2026-02-18 22:24:05 - baoquankhu1.vn
Analysis Recap: Is Beyond Air Inc showing insider buyingBuy Signal & AI Driven Stock Reports - baoquankhu1.vn
Aug Outlook: How liquid is Beyond Air Inc stockTrade Entry Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
XAIR Technical Analysis & ETF Price Forecast - Intellectia AI
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Intellectia AI
MSN Money - MSN
Leishen Energy's FY2025 Financial Results Analysis - Intellectia AI
Analyst Warns: Failure of NeuroNOS Acquisition Could Pressure Beyond Air’s Strategy, Finances, and Stock Price - TipRanks
Beyond Air Inc Stock (XAIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):